Back to top
more

Dentsply Sirona (XRAY)

(Real Time Quote from BATS)

$13.22 USD

13.22
6,303,612

-0.46 (-3.36%)

Updated Aug 7, 2025 03:43 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

What's in Store for Thermo Fisher (TMO) in Q4 Earnings?

by Zacks Equity Research

Strength in segments is expected to get reflected in Thermo Fisher's (TMO) fourth-quarter and 2019 top-line numbers.

Zacks Equity Research

Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?

by Zacks Equity Research

Illumina (ILMN) is upbeat about fourth-quarter and fiscal 2019 results after a strong third-quarter performance.

Zacks Equity Research

Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sweta Killa headshot

10 Top-Ranked S&P 500 Stocks Outperforming in 2020

by Sweta Killa

The rally has been broad based and there are winners across various corners of the space.

Zacks Equity Research

Masimo Posts Solid Preliminary 2019 Results, Issues Guidance

by Zacks Equity Research

Higher revenues and upbeat 2020 outlook benefit Masimo's (MASI) preliminary full-year 2019 results.

Zacks Equity Research

Baxter Posts Upbeat Q4 Preliminary Results, Issues Guidance

by Zacks Equity Research

Higher revenues, growth in all geographic segments and six business units benefit Baxter's (BAX) Q4 preliminary operating results.

Zacks Equity Research

Here's Why You Should Hold on to Cardinal Health Stock Now

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.

Zacks Equity Research

Intuitive Surgical (ISRG) Up on Solid Preliminary Q4 Results

by Zacks Equity Research

Higher revenues and growth in worldwide da Vinci procedure volume benefit Intuitive Surgical's (ISRG) preliminary Q4 results.

Zacks Equity Research

Veeva Systems Boosts Product Portfolio With New Application

by Zacks Equity Research

Veeva Systems (VEEV) introduces Veeva Vault Payments, which is likely to bolster the company's already robust product portfolio.

Zacks Equity Research

Here's Why You Should Invest in HMS Holdings (HMSY) Stock Now

by Zacks Equity Research

HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services.

Zacks Equity Research

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.

Zacks Equity Research

XRAY or ALGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

XRAY vs. ALGN: Which Stock Is the Better Value Option?

Zacks Equity Research

Why Is Dentsply (XRAY) Up 1.7% Since Last Earnings Report?

by Zacks Equity Research

Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sriparna Ghosal headshot

3 Orthodontic Stocks to Keep an Eye On

by Sriparna Ghosal

Growth in the orthodontics market has been primarily led by rising focus of vendors on emerging markets, such as Asia-Pacific and LAMEA.

Zacks Equity Research

Here's Why You Should Add Veeva (VEEV) to Your Portfolio Now

by Zacks Equity Research

Buoyed by a solid fiscal third quarter, Veeva (VEEV) raises its fiscal 2020 revenue guidance.

Zacks Equity Research

Here's Why You Should Retain McKesson (MCK) Stock for Now

by Zacks Equity Research

McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market. However, rising pricing pressure remains a concern.

Zacks Equity Research

Here's Why You Should Hold on to Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.

Zacks Equity Research

Here's Why You Should Hold on to OPKO Health (OPK) Stock Now

by Zacks Equity Research

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.

Zacks Equity Research

XRAY vs. ALGN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

XRAY vs. ALGN: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why You Should Hold on to Masimo (MASI) Stock Now

by Zacks Equity Research

Masimo (MASI) raises 2019 revenue and EPS guidance.

Zacks Equity Research

Here's Why You Should Retain PRA Health (PRAH) Stock Now

by Zacks Equity Research

PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, escalating direct costs remain a woe.

Zacks Equity Research

Cooper Companies' CVI Unit Gets FDA Nod, To Boost Eye Health

by Zacks Equity Research

Cooper Companies' (COO) CVI Unit has receives FDA approval for its MiSight 1 day contact lens, which complements its commitment to eye health innovation.

Zacks Equity Research

Here's Why You Should Hold on to Becton, Dickinson Stock Now

by Zacks Equity Research

Becton, Dickinson (BDX) expects tariffs to impact its bottom line in first-quarter fiscal 2020.

Zacks Equity Research

Here's Why You Should Hold on to PerkinElmer Stock for Now

by Zacks Equity Research

PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

Zacks Equity Research

Here's Why You Should Hold Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.